Metabotropic glutamate receptor 4 (mGlu 4)-positive allosteric modulators for the treatment of Parkinson's disease

Historical perspective and review of the patent literature

Craig W. Lindsley, Corey R Hopkins

Research output: Contribution to journalReview article

25 Citations (Scopus)

Abstract

Introduction: Metabotropic glutamate receptor 4 (mGlu 4) is a group III GPCR and has been demonstrated to play a major role in a number of therapeutic areas within the CNS. As the orthosteric site of all glutamate receptors is highly conserved, modulating mGlu 4 via allosteric modulation has emerged as a very attractive mode-of-action and has been validated preclinically in a number of animal models for Parkinson's disease, anxiety, pain, and neuroinflammation. Areas covered: In this review, the patent literature for mGlu 4-positive allosteric modulators over the past 4 years will be provided. Patents from all companies are discussed and an overview of the chemical matter and relevant biological properties will be given. Expert opinion: Although there has yet to be an mGlu 4-positive allosteric modulator progressed into clinical trials, there is a wealth of preclinical data from the primary literature that shows the promise of this emerging target. A number of academic and industry laboratories have recently published exciting patent data covering a multitude of chemical matter. Positive allosteric modulation of mGlu 4 remains one of the more attractive non-dopaminergic therapies for Parkinson's disease, as well as emerging data for other indications such as pain, neuroinflammation, schizophrenia and diabetes, which could potentially make mGlu 4 a significant therapeutic target going forward.

Original languageEnglish (US)
Pages (from-to)461-481
Number of pages21
JournalExpert Opinion on Therapeutic Patents
Volume22
Issue number5
DOIs
StatePublished - May 1 2012

Fingerprint

Patents
Parkinson Disease
Therapeutics
Pain
Glutamate Receptors
Expert Testimony
metabotropic glutamate receptor 4
Schizophrenia
Industry
Anxiety
Animal Models
Clinical Trials

Keywords

  • CNS
  • Metabotropic glutamate receptor 4
  • Non-dopaminergic therapies
  • Parkinson's disease
  • Positive allosteric modulators

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

@article{b7835150963b47acbb69f37aba45addc,
title = "Metabotropic glutamate receptor 4 (mGlu 4)-positive allosteric modulators for the treatment of Parkinson's disease: Historical perspective and review of the patent literature",
abstract = "Introduction: Metabotropic glutamate receptor 4 (mGlu 4) is a group III GPCR and has been demonstrated to play a major role in a number of therapeutic areas within the CNS. As the orthosteric site of all glutamate receptors is highly conserved, modulating mGlu 4 via allosteric modulation has emerged as a very attractive mode-of-action and has been validated preclinically in a number of animal models for Parkinson's disease, anxiety, pain, and neuroinflammation. Areas covered: In this review, the patent literature for mGlu 4-positive allosteric modulators over the past 4 years will be provided. Patents from all companies are discussed and an overview of the chemical matter and relevant biological properties will be given. Expert opinion: Although there has yet to be an mGlu 4-positive allosteric modulator progressed into clinical trials, there is a wealth of preclinical data from the primary literature that shows the promise of this emerging target. A number of academic and industry laboratories have recently published exciting patent data covering a multitude of chemical matter. Positive allosteric modulation of mGlu 4 remains one of the more attractive non-dopaminergic therapies for Parkinson's disease, as well as emerging data for other indications such as pain, neuroinflammation, schizophrenia and diabetes, which could potentially make mGlu 4 a significant therapeutic target going forward.",
keywords = "CNS, Metabotropic glutamate receptor 4, Non-dopaminergic therapies, Parkinson's disease, Positive allosteric modulators",
author = "Lindsley, {Craig W.} and Hopkins, {Corey R}",
year = "2012",
month = "5",
day = "1",
doi = "10.1517/13543776.2012.679437",
language = "English (US)",
volume = "22",
pages = "461--481",
journal = "Expert Opinion on Therapeutic Patents",
issn = "1354-3776",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Metabotropic glutamate receptor 4 (mGlu 4)-positive allosteric modulators for the treatment of Parkinson's disease

T2 - Historical perspective and review of the patent literature

AU - Lindsley, Craig W.

AU - Hopkins, Corey R

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Introduction: Metabotropic glutamate receptor 4 (mGlu 4) is a group III GPCR and has been demonstrated to play a major role in a number of therapeutic areas within the CNS. As the orthosteric site of all glutamate receptors is highly conserved, modulating mGlu 4 via allosteric modulation has emerged as a very attractive mode-of-action and has been validated preclinically in a number of animal models for Parkinson's disease, anxiety, pain, and neuroinflammation. Areas covered: In this review, the patent literature for mGlu 4-positive allosteric modulators over the past 4 years will be provided. Patents from all companies are discussed and an overview of the chemical matter and relevant biological properties will be given. Expert opinion: Although there has yet to be an mGlu 4-positive allosteric modulator progressed into clinical trials, there is a wealth of preclinical data from the primary literature that shows the promise of this emerging target. A number of academic and industry laboratories have recently published exciting patent data covering a multitude of chemical matter. Positive allosteric modulation of mGlu 4 remains one of the more attractive non-dopaminergic therapies for Parkinson's disease, as well as emerging data for other indications such as pain, neuroinflammation, schizophrenia and diabetes, which could potentially make mGlu 4 a significant therapeutic target going forward.

AB - Introduction: Metabotropic glutamate receptor 4 (mGlu 4) is a group III GPCR and has been demonstrated to play a major role in a number of therapeutic areas within the CNS. As the orthosteric site of all glutamate receptors is highly conserved, modulating mGlu 4 via allosteric modulation has emerged as a very attractive mode-of-action and has been validated preclinically in a number of animal models for Parkinson's disease, anxiety, pain, and neuroinflammation. Areas covered: In this review, the patent literature for mGlu 4-positive allosteric modulators over the past 4 years will be provided. Patents from all companies are discussed and an overview of the chemical matter and relevant biological properties will be given. Expert opinion: Although there has yet to be an mGlu 4-positive allosteric modulator progressed into clinical trials, there is a wealth of preclinical data from the primary literature that shows the promise of this emerging target. A number of academic and industry laboratories have recently published exciting patent data covering a multitude of chemical matter. Positive allosteric modulation of mGlu 4 remains one of the more attractive non-dopaminergic therapies for Parkinson's disease, as well as emerging data for other indications such as pain, neuroinflammation, schizophrenia and diabetes, which could potentially make mGlu 4 a significant therapeutic target going forward.

KW - CNS

KW - Metabotropic glutamate receptor 4

KW - Non-dopaminergic therapies

KW - Parkinson's disease

KW - Positive allosteric modulators

UR - http://www.scopus.com/inward/record.url?scp=84861523769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861523769&partnerID=8YFLogxK

U2 - 10.1517/13543776.2012.679437

DO - 10.1517/13543776.2012.679437

M3 - Review article

VL - 22

SP - 461

EP - 481

JO - Expert Opinion on Therapeutic Patents

JF - Expert Opinion on Therapeutic Patents

SN - 1354-3776

IS - 5

ER -